A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada

NCT04567095 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-10-23

No results posted yet for this study

Summary

This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Patients in Canada.

Conditions

  • Uterine Fibroids

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Ahunna Ukah · Allergan

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04567095 on ClinicalTrials.gov